Who owns ACRIVON THERAPEUTICS INC?
- Ticker: ACRV
- CUSIP Number: 004890109
Tip: Access positions for across all investors
Analyze quarterly positions in Acrivon Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acrivon Therapeutics stock
Who bought or sold ACRIVON THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 8.3M | $12M | 0% | Mar 2026 |
|
| Sands Capital Ventures | 2.1M | $3.0M | 0% | Mar 2026 |
|
| Wellington Management Company | 888k | $1.2M | 0% | Mar 2026 |
|
| Acadian Asset Management | 846k | $1.2M | 46% | Mar 2026 |
|
| Renaissance Technologies | 758k | $1.1M | 20% | Mar 2026 |
|
| Vanguard Capital Management | 722k | $1.0M | 100% | Mar 2026 |
|
| Marshall Wace | 560k | $779k | 13% | Mar 2026 |
|
| Two Sigma Investments | 389k | $541k | -33% | Mar 2026 |
|
| Jane Street | 240k | $333k | -30% | Mar 2026 |
|
| Geode Capital Management | 236k | $329k | 19% | Mar 2026 |
|
| BlackRock | 209k | $290k | 2% | Mar 2026 |
|
| GSA Capital Partners | 187k | $260k | 100% | Mar 2026 |
|
| Bridgeway Capital Management | 159k | $221k | 270% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 108k | $150k | 100% | Mar 2026 |
|
| State Street Corporation | 67k | $93k | 0% | Mar 2026 |
|
| XTX Topco | 67k | $93k | 225% | Mar 2026 |
|
| Northern Trust | 49k | $68k | -23% | Mar 2026 |
|
| Morgan Stanley | 37k | $51k | -22% | Mar 2026 |
|
| UBS Group | 35k | $48k | -90% | Mar 2026 |
|
| PanAgora Asset Management | 34k | $47k | 100% | Mar 2026 |
|
| Squarepoint Ops | 28k | $38k | 5% | Mar 2026 |
|
| Springbok Capital Management | 24k | $33k | -50% | Mar 2026 |
|
| Marex Group | 20k | $28k | 100% | Mar 2026 |
|
| Dimensional Fund Advisors | 18k | $26k | 0% | Mar 2026 |
|
| Bank of America Corporation | 17k | $23k | 100% | Mar 2026 |
|
| Goldman Sachs Group | 15k | $21k | -88% | Mar 2026 |
|
| Two Sigma Securities | 12k | $16k | 100% | Mar 2026 |
|
| AAFCPAs Wealth Management | 11k | $15k | 0% | Mar 2026 |
|
| FMR | 9.4k | $13k | 9% | Mar 2026 |
|
| Federated Investors | 7.9k | $11k | 41% | Mar 2026 |
|
| Barclays | 5.9k | $8.3k | -76% | Mar 2026 |
|
| Tower Research Capital | 4.5k | $6.3k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 4.5k | $6.2k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 3.0k | $4.2k | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 634.00 | $881.006400 | 0% | Mar 2026 |
|
| NISA Investment Advisors | 584.00 | $811.993600 | 0% | Mar 2026 |
|
| Redwood Park Advisors | 500.00 | $695.000000 | 0% | Mar 2026 |
|
| Russell Investments | 481.00 | $669.022900 | 0% | Mar 2026 |
|
| Federation des caisses Desjardins du Quebec | 400.00 | $556.000000 | 0% | Mar 2026 |
|
| Steward Partners Investment Advisory | 326.00 | $453.009600 | 100% | Mar 2026 |
|
| SBI Securities | 74.00 | $103.000600 | 0% | Mar 2026 |
|
| Royal Bank of Canada | 25.00 | $0 | 100% | Mar 2026 |
|
| Caitong International Asset Management | 4.00 | $6.000000 | 100% | Mar 2026 |
|
Who sold out of Acrivon Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Citadel Advisors | Dec 2025 | 1.6M | $4.0M |
| Acorn Capital Advisors | Dec 2025 | 405k | $977k |
| Two Sigma Advisers | Dec 2025 | 334k | $804k |
| Millennium Management | Dec 2025 | 122k | $293k |
| Baker Bros. Advisors | Dec 2025 | 23k | $55k |
| Quadrature Capital | Dec 2025 | 21k | $50k |
| Vermillion & White Wealth Management Group | Dec 2025 | 18k | $44k |
| Schonfeld Strategic Advisors | Dec 2025 | 16k | $40k |
| Susquehanna International | Dec 2025 | 12k | $30k |
| Point72 Asset Management | Dec 2025 | 11k | $26k |
| EverSource Wealth Advisors | Dec 2025 | 373.00 | $899.004600 |
| Optima Capital | Dec 2025 | 278.00 | $670.007800 |